Heidi, an AI tool for clinicians that has become deeply embedded within the UK’s National Health Service (NHS), has closed a $65 million Series B funding round. The round, led by Point72 Private Investments, values the company at $465 million and brings its total funding to nearly $100 million.
The company’s AI platform acts as a "care partner" for doctors, automating administrative tasks like clinical documentation and follow-up communications. Its traction is undeniable: according to the company, Heidi is already used by over 60% of NHS General Practitioners (GPs), supporting more than 340,000 patient consultations every week and saving an estimated 3 million clinical hours annually in the UK alone.
This isn't just about GP offices. The new funding is set to accelerate Heidi’s expansion into secondary care and global markets. The company has already secured a major deployment with Modality Partnership, the NHS’s largest GP super-partnership, and is running pilots with major hospital groups, including Cambridge University Hospitals and NHS Trusts serving millions in London and Lancashire.
From GPs to global expansion
While its NHS footprint is its anchor, Heidi’s global reach is expanding rapidly. The company reports supporting over two million patient consultations a week across 116 countries and in 110 languages. Over the last 18 months, it claims to have supported 73 million patient consults globally.
"It is untenable that healthcare demand continues to rise while clinical time continues to shrink," said CEO and co-founder Dr. Thomas Kelly in a statement. He positions Heidi as a tool to expand clinical capacity without compromising clinician wellbeing.
To fuel its growth, Heidi is doubling its UK headcount and investing in the US and Canadian markets. The company also announced two significant hires to its leadership team: Paul Williamson, former Head of Revenue at Plaid, joins as Chief Revenue Officer, and Dr. Simon Kos, former Chief Medical Officer of Microsoft, joins as Global Chief Medical Officer.
The move signals a clear intent to scale a tool that investors see as a "clinician-led movement." Ferdi Sigona, a partner at continuing investor Latitude, noted, "When doctors themselves are championing a tool so passionately... you know we're backing a company with universal appeal across healthcare." With fresh capital and seasoned leadership, Heidi is betting it can replicate its NHS success on a global scale.
